PrE0102 – Published

The results from the PrE0102 study, a Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Fulvestrant Plus Everolimus in Post-Menopausal Patients With Hormone-Receptor Positive Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy was published by Kornblum N, Zhao F, Manola J, The article appeared online before print in the Journal of Clinical Oncology on April 17, 2018. NCT01797120, doi: 10.1200/JCO.2017.76.9331

« Return to News